PROMISE Framework for Standardized PET Imaging of Prostate Cancer
The Prostate Cancer Molecular Imaging Standardized Evaluation
(PROMISE) criteria were established in 2018 and revised in 2023. PROMISE guides the interpretation of PSMA-PET scans. These scans are advanced diagnostic tools that identify prostate cancer and its dissemination throughout the body.
The prestigious German University Medicine Award 2025 has been awarded to the PROMISE registry. The award ceremony will take place during the Day of University Medicine on November 26, 2025 in Berlin.
The German University Medicine Award is presented annually by the Association of Medical Faculties and the German University Hospitals Alliance. In addition to honoring outstanding teamwork, the award honors innovation, successful translation of research projects into patient care, and the societal impact of medical achievements.
Why is PROMISE needed?
- Identifying whether the cancer has metastasized.
- Detecting the recurrence of prostate cancer following surgery or radiation therapy.
- Assessing suitability for PSMA-targeted treatments.
The PROMISE system organizes information from PSMA-PET scans to facilitate accurate and clear communication between physicians and hospitals. In addition, PROMISE reveals important information for the individual patient prognosis.
How PROMISE works
PROMISE classifies the extent of disease on a PSMA-PET scan by categorizing it into specific regions: local (T), lymph node (N), and organ (M) spread. Disease extent and location is reported for all body regions and summarized in a comprehensive diagnosis code.
Standardized reading of PSMA-PET can be performed using the free Web Application ePROMISE.
Standardized reading of PSMA-PET can also be performed on paper using the PROMISE Pocket Card
 | Pocket Card on PROMISE Pocket Card for Standardized PSMA-PET reporting PROMISE Pocket Card.pdf (212.66KB) |
Pocket Card for Standardized PSMA-PET reporting
| PROMISE Pocket Card.pdf (212.66KB) |
PROMISE PET Registry
PSMA-PET imaging and the PROMISE framework are linked to prostate cancer outcomes. To deepen our understanding of the relationship between PET imaging and patient survival, we have established an international registry study for PET imaging centers.